Ovarian Cancer Clinical Trial
A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.
Female patient, 18 years of age or older diagnosed with an ovarian adnexal mass, or in follow-up due to the presence of BRCA1/2 and other germline DNA variants.
Patient reviewed, understood, and provided the PI with written informed consent to allow blood specimen to be used for research and release of medical information.
Patient is less than 18 years of age
Patient is not being treated in the U.S.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Chandler Arizona, 85224, United States
Lake Worth Florida, 33461, United States
Columbus Georgia, 31901, United States
Eden Prairie Minnesota, 55344, United States
New Hyde Park New York, 11040, United States
New Hyde Park New York, 11042, United States
Cincinnati Ohio, 45211, United States
Lancaster Pennsylvania, 17601, United States
Austin Texas, 78748, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.